DOCSLIB.ORG

2006 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2006 Annual Report Centenary Institute report annual 06 OUR LOGO The letter “C” set in sandstone in the logo, has dual symbolism. It reflects our commitment to cancer research and, as the Roman Numeral for 100, it represents our association with the Centenaries of the University of Sydney Medical School and Royal Prince Alfred Hospital. Our mission To improve the quality of life for all Australians through excellence in medical research Centenary Institute Annual Report 2006 www.centenary.org.au 3 Contents Page 2006 Highlights 4 Director’s Report 6 From The Chairman 7 Report from Incoming Executive Director 8 Board of Governors 9 Our History 11 Organisational Chart 12-13 Research Groups 14 Cell Biology 14 Gene and Stem Cell Therapy 18 Liver Immunobiology 20 Molecular Cardiology 25 Mycobacterial Research 26 T Cell Biology 29 Core Facilities 31 Postgraduate Training Programme 33 2006 Seminar Series 35 2006 Publications 38 2006 Presentations 41 Centenary Committees 47 2006 Staff List 48 2007 – The Year Ahead 51 Fundraising 53 Centenary Institute Annual Report 2006 4 2006 Highlights • Centenary Institute’s Agnes Ginges Centre for Molecular capacity of infected macrophages to die through Cardiology, headed by Associate Professor Chris apoptosis and kill mycobacteria. In separate studies Semsarian, have identified several ‘killer’ genes the group showed that the recently recognised believed to be responsible for sudden cardiac death cytokine IL-23 is effective for increasing the immune (SCD) following tests on more than 400 Australian response and protective effect of DNA vaccines against families with a history of heart disease. The group is TB and that this cytokine can compensate for IL-12 amongst the first to report the association between deficiency in controlling TB in mice. two gene mutations and disease severity and increased risk of SCD. Grants 2006 • Associate Professor Barbara Fazekas de St.Groth, • NHMRC Project Grant, Genetic Modulation of the host together with colleagues, has developed a new blood response to pulmonary TB test to detect a rare but important subset of white - Dr Bernadette Saunders, Professor Warwick Britton blood cells, known as regulatory T cells. It is possible and Professor John Rasko the test will be used in the diagnosis and monitoring of autoimmune and infectious diseases. The work was • NHMRC Project Grant, Manipulating immunity to published in the Journal of Experimental Medicine in Mycobacterium tuberculosis with novel vaccines and July and submitted as PCT patent application in immunotherapeutics August. License negotiations with a reagent company - Dr Jamie Triccas, Professor Warwick Britton interested in marketing the kit are ongoing. • NHMRC Project Grant, Diseases of Aminoacid • Professor John Rasko, Head of the Centenary Institute Transport: Genetic, Molecular and Biochemical of Cancer Medicine and Cell Biology’s Gene and Stem Studies, Cell Therapy laboratory, reported in Nature Medicine the - Professor John Rasko, in collaboration with Dr results of an international collaborative study Juleen Cavanaugh and Dr Stefan Broer from ANU. involving Haemophilia patients from the RPAH. The clinical trial demonstrated the safe introduction of a • NHMRC New Investigator Project Grant Regulation of clotting factor gene to achieve a substantial Angiotensin-Converting Enzyme 2 Expression in Liver improvement in the levels of the essential protein, Injury Factor IX. Insights into an immune response following - Dr Fiona Warner the gene therapy may provide opportunities for the • NHMRC Enabling Grant, Genetic Repositories Australia ultimate cure of this serious disease. - Professor Peter Schofield (University of NSW), • Dr Patrick Bertolino and colleagues have shown for the Professor John Rasko and colleagues first time how liver cells make contact with disease- • Sydney Cancer Centre Grant, Mesenchymal stem cell fighting T cells in the body. Electron microscopy gene therapy for prostate cancer images captured minuscule extensions produced by the - Dr Rose Martiniello-Wilks circulating T cells reaching across the openings in the vessel walls to liver cells. In hepatitis infection the • Sydney Cancer Centre Grant, The role of CTCF and openings are closed to protect the liver from damage BORIS transcription factors in cancer by the immune system. This research was published in - Professor John Rasko the November issues of the journals Hepatology and • National Heart Foundation Project Grant, Novel Journal of Hepatology. insights into the genetic basis of hypertrophic • Professor Warwick Britton’s mycobacterial laboratory cardiomyopathy: candidate genes related to calcium demonstrated that variations in the purinergic receptor handling on the surface of a population of human white blood - Associate Professor Chris Semsarian cells called macrophages determines the ability of • University of Sydney Major Equipment Grant, NHMRC these cells to kill M. tuberculosis and that a genetic Equipment Grant and a Gift from the Clive and Vera variant (polymorphism) of the receptor is associated Ramaciotti Foundation for the purchase of IVIS 100 with the risk of developing tuberculosis in two In vivo Bioluminescence Imaging System separate populations of TB patients in Sydney. - Professor John Rasko, Dr John Allen, Dr Patrick Purinergic receptors are a family of plasma membrane Bertolino, Professor Warwick Britton, Associate molecules involved in several cellular functions Professor Barbara Fazekas & colleagues, including vascular reactivity, apoptosis (programmed cell death) and cytokine secretion. This genetic variant of the receptor was associated with reduced Centenary Institute Annual Report 2006 www.centenary.org.au 5 • Perpetual Trust, Equipment Grant Prevention of Ling S, Allen JD. Australian Provisional Patent Application. sudden death in Australian families entitled ‘Assay for response to proteasome inhibitors’. - Associate Professor Chris Semsarian Centenary Institute of Cancer Medicine and Cell Biology. • Perpetual Trust, Equipment Grant Improving animal Reference: 20124AUV00. Filed Dec 8, 2006. models of multi-drug resistant human disease Student Awards: - Dr John Allen and Dr Bernadette Saunders • University of Sydney NHMRC Equipment Grant Ben Roediger (PhD student, T Cell Biology) was selected to - Prof Geoff McCaughan, Dr Mark Gorrell,Dr Alexandra give an oral presentation in a Plenary session at the 9th Sharland, A/Prof Paul S Haber, Dr Bret W Church, Dr International Conference on Dendritic Cells in Edinburgh. Patrick Bertolino He was awarded a Faculty of Medicine Travelling Fellowship of $5,000 to attend the meeting. • Rebecca L Cooper Foundation, Live animal imaging for gene expression Alex Spencer (PhD student, T Cell Biology) was awarded a - Professor John Rasko Keystone Travel Scholarship to attend the Determinants of Host Resistance, Susceptibility or Immunopathology to • Rebecca L Cooper Foundation, Gene expression in Pathogens conference at Steamboat Springs in Colorado. pulmonary tuberculosis infection - Professor Warwick Britton Sioh-Yang Tan (PhD student, T Cell Biology) was awarded a Keystone Travel Scholarship to attend the Tolerance, • Leukaemia Foundation, Non-coding gene control of Autoimmunity and Immune Regulation conference at myelopoiesis Breckenridge in Colorado. - Professor John Rasko Scholarships Patents Ms Christine Chiu - NHMRC/National Heart Foundation Dora Hnin Aung, Pat Iversen and John Rasko USA Provisional Lush (Biomedical) (Molecular Cardiology). patent filed by AVI Biopharma, Corvallis, OR, entitled ‘Antisense Composition and Method for Inhibition of Mr Robin Mihrshahi - Alumni Scholarship for Health miRNA Biogenesis’. Inventors, September 2006. Sciences and an Australian Postgraduate Award (T Cell Biology). Dr Lye Lin Ho - Research Scholar Award, Cancer Institute NSW (Cancer Drug Resistance) Dr Silvia Ling - Research Scholar Award, Cancer Institute NSW (Cancer Drug Resistance) Dr Stephen Larsen - Research Scholar Award Cancer Institute NSW (Gene & Stem Cell Therapy Group) Publications 2006 was a very successful year for the Centenary Institute with respect to publications in high impact journals. Researchers published a total of 57 manuscripts, books and chapters throughout the year. A detailed list can be found on pages 38 to 40 of this report. Centenary Institute Annual Report 2006 6 Director’s Report 2006 has been a landmark year for the Centenary Institute. for their contribution to Centenary over many years. Their The Foundation Director, Professor Tony Basten, AO, FAA, departure, however, creates opportunities for rejuvenation FTSE formally resigned at the end of 2005, having earlier of Centenary’s scientific staff and its scientific directions, stood down as Executive Director in October. He was and new recruits to the scientific staff will be featured in appointed Emeritus Professor at the University of Sydney Centenary Newsletters. Centenary’s long-standing General and stayed with Centenary in an honorary capacity until Manager, Ms Denyse Bartimote, left Centenary employment mid 2006, when he left to take up a prestigious Visiting in January, and Dr Nick Pearce took on the role of Acting Fellowship at Cambridge University. Professor Basten takes General Manager. Ms Elaine Cook resigned and Viraf the best wishes and gratitude of all staff and friends of Variava has taken on the role of Acting Finance Manager. Centenary, and he leaves knowing that he has placed Ms Judith Barry retired during 2006, and Ms Nanette Centenary in a very sound position to face the future. Herlihen
Load more

Recommended publications
  • The Bursa of Fabricius Award 12 ASI Councillors' News 13 Caption Competition 16 ASI Inc
    NEWSLETTER Australasian Society for Immunology Incorporated PP 341403100035 ISSN 1442-8725 March 2004 How to win a Nobel Prize in Physiology or Medicine Gordon Ada, John Curtin School of Medical Research When one thinks of winners of Nobel Prizes November to celebrate his contributions and at the Institute for 19 years when Frank came in these disciplines, there is a tendency to achievements. Peter and Rolf were present as to visit me in 1967. He told me he had visualize mature scientists who after many well as many of his past students (from 1972 relinquished the Headship of the Department years of laboratory work have accumulated to 2003) and others who worked in the of Microbiology to become the Director of lots of evidence to prove a particular concept Department, mainly in the 1970s. The the John Curtin School. He asked whether I or theory. This certainly happens, but there contributions, especially by past students, would let my name go forward as a candidate are many other situations. For example, one were remarkable for the variety of topics to succeed him as Head of the Microbiology recipient has provided the concept which a presented. Department? I decided yes, because under co-recipient has independently proven it to Frank Fenner, the Microbiology Department be correct. (e.g. Immunological tolerance, In the late 1960s I was happily working at the had reached international status and if I went Burnet and Medawar, 1960). In contrast, the Walter and Eliza Hall Institute (WEHI) with there, I could bring virology and immunology 1996 Prize resulted from a rather unusual Gus Nossal as a close colleague.
    [Show full text]
  • Influenza Susceptibility Linked to Variable Responses to Interferons in the Lung
    MEDIA RELEASE Wed 11th December 2019 Influenza susceptibility linked to variable responses to interferons in the lung Researchers at the Centenary Institute and the University of Sydney have discovered a key reason as to why the influenza virus is so effective at establishing infection and causing damage in the lungs. They found that a group of lung-cells, following influenza infection, responded only poorly to interferons (the signalling proteins that help defend the body against viral attack). The research could pave the way for the development of new and improved anti-influenza drugs and vaccines, to both improve health and to save lives. “Interferons are critically essential to our defence against pathogens including the influenza virus,” said Associate Professor Carl Feng, senior study author from the Centenary Institute and the University of Sydney. “The proteins are so named because they ‘interfere’ with the ability of viruses to multiply in the body.” “It’s been known for a long time that during influenza, lung cells and immune cells in the lungs secrete interferons causing virus-infected cells to initiate anti-viral defences,” said Associate Professor Feng. “However, how interferons actually undertake this protective activity is still not understood because the signalling proteins can act on hundreds of different types of cells in our body,” he said. In their study, Associate Professor Feng and colleagues have generated a new tool to identify which cells respond to interferons in influenza infected mice. The goal was to work out whether the outcome of infection and interferon signalling differed between different cell types. What the researchers have demonstrated in the study is that not every cell type reacts equally to the interferons, even when they are in close proximity to each other.
    [Show full text]
  • Survey of Commercial Outcomes from Public Research (Scopr) 2019 Report
    techtransfer.org.au SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH (SCOPR) 2019 REPORT Survey and report delivered by FOREWORD There is an ever-present imperative to capture the commercial value of our research endeavour for our future wellbeing. To do so strategically, decision makers from laboratory, institutional and government levels need insights into how the research sector is currently engaging with industry to transfer knowledge and innovation, and thereby deliver benefits to our society from the fruits of our research. For many years in Australia there has been a focus on improving innovation metrics, thus I am delighted to acknowledge the initiative of gemaker and Knowledge Commercialisation Australasia (KCA) in producing the inaugural Survey of Commercial Outcomes from Public Research (SCOPR). The SCOPR takes its lead from the National Survey of Research Commercialisation (NSRC) produced since 2000 by the Department of Industry, Science, Energy and Resources. To avoid duplication, the Department has decided to cease the NSRC and will work with KCA to share knowledge, and access data collected by SCOPR. As we face the COVID-19 pandemic, effective knowledge transfer is more important than ever, so I hope that this report will spur our research institutions to even greater achievements. Realising effective knowledge transfer will depend on having skilled commercialisation professionals who can help researchers turn great ideas into beneficial products and services. I applaud KCA’s support for technology transfer professionals
    [Show full text]
  • Discovery First Step to New Therapies Many of Our Scientists Have Achieved Strong Results in Their Research Throughout the Year
    Newsletter of the Centenary Institute OCTOBER 08 LuminesCent Dr Mika Jormakka hopes to improve treatments for diseases like cancer by mapping complex Welcome to the October 2008 issue of structures called membrane proteins. LuminesCent, wrapping up a very busy and exciting year for the Centenary Institute. Discovery first step to new therapies Many of our scientists have achieved strong results in their research throughout the year. In this edition we In an Australian first, scientists at the Centenary Institute have mapped the feature two, Dr Mika Jormakka (page 1) and Associate anatomy of a membrane protein. This exciting discovery has the potential to turn Professor Chris Semsarian (page 5), who had their work the way we discover new drugs on its head and reduce the development time published in highly respected international journals. for new treatments. One of our promising young researchers, Dr Jeff Holst, of “These membrane proteins are the target for 70% of all therapeutic drugs so the Gene and Stem Cell Therapy program, talks about an increased understanding of them is vital for future drug discoveries,” said his investigations into prostate cancer, the most common Centenary Institute Executive Director, Professor Mathew Vadas. cancer diagnosed in Australian men, on page 4. The Centenary Institute recently unveiled a confocal Publishing in the prestigious international journal, Nature Structural & Molecular microscope that produces 3D images and video for Biology, Dr Mika Jormakka, head of Centenary’s Structural Biology laboratory, says improved investigation of diseases such as cancer and understanding membrane protein structures will help develop better treatments heart disease. Read about it on page 2.
    [Show full text]
  • 2005 Annual Report
    Centenary Institute report annual 05 OUR LOGO The letter “C” set in sandstone in the logo, has dual symbolism. It reflects our commitment to cancer research and, as the Roman Numeral for 100, it represents our association with the Centenaries of the University of Sydney Medical School and Royal Prince Alfred Hospital. Our mission To improve the quality of life for all Australians through excellence in medical research Centenary Institute Annual Report 2005 www.centenary.org.au 3 Contents Page 2005 Highlights 4 Director's Report 7 Farewell to Professor Antony Basten 8 Interim Director's Report 10 Board Governors 11 Our History 13 Organisational Chart 14 Research Groups 16 Cell Biology 16 Antibody Gene Recombination & Mutation 16 Cancer Drug Resistance 17 Lymphocyte Differentiation 18 Molecular & Cellular Responses 19 Type 1 Diabetes 20 Cellular Immunity 21 Gene and Stem Cell Therapy 22 Liver Immunobiology 24 Liver Immunology 24 Molecular Hepatology 25 Transplantation 26 Molecular Cardiology 28 Mycobacterial Research 29 Host Responses to Infection 30 Vaccine Development & Mycobacterial Pathogenesis 31 T Cell Biology 32 Core Facilities 34 Postgraduate Training Programme 36 2005 Seminar Series 38 2005 Publications 40 2005 Presentations 43 Centenary Committees 51 2005 Staff List 52 Research Groups 52 2006 - The Year Ahead…. 55 Fundraising 56 Centenary Institute Annual Report 2005 4 2005 Highlights Major equipment upgrade • Associate Professor Chris Semsarian, head of Centenary's Agnes Ginges Centre for Molecular In June 2005 Centenary took delivery of three new flow Cardiology, was the runner-up in the 2005 Royal Prince cytometers from BD Biosciences valued at $1.7 million, Alfred Research Medal presentations.
    [Show full text]
  • Investing in Audiences – ABC Annual Report 2017 – Volume 2
    INVESTING IN VOLUME II VOLUME AUDIENCES ANNUAL REPORT 2017 Carolyn Duchene in Art Bites: The Glass Bedroom We make content for all Australians, about all Australians. HOW WE OPERATE RESPONSIBILITY ACCOUNTABILITY Editorial quality 4 Corporate Corporate Responsibility 30 Governance 54 Infrastructure and Operations 8 Corporate Responsibility Bonner Committee 62 in a Broadcasting People 12 ABC Advisory Context 34 Council 66 Work Health Environmental and Safety 18 Responsibility 38 Corporate Services 22 Social Responsibility 44 ii AUSTRALIAN BROADCASTING CORPORATION ANNUAL REPORT 2017 In Volume I you will find: Who we are Where to find us What we do Transformation Audience Metrics Index Chico Wanybarrnga, Dino Wanybarrnga, Jerome Lilypiyana and ANNUAL PERFORMANCE Joseph Smith in Black As. Image: Rebel Films STATEMENTS ABC Annual Performance Statements 2016–17 70 FINANCIAL STATEMENTS 80 APPENDICES 134 COMPLIANCE INDEX 186 190 INDEX Contents 1 How we operate Anh’s Brush with Fame 2 AUSTRALIAN BROADCASTING CORPORATION ANNUAL REPORT 2017 How we operate The ABC provides extraordinary content for Australians by building an engaged, operate creative and innovative workforce that reflects and supports the broader community How we operate 3 Editorial quality The ABC Editorial Policies are principles and standards applied across the Corporation, to ensure continuous high-quality output and performance. Editorial reviews and the ABC’s responses are published on the ABC’s corporate website: http://about.abc.net.au/how-the-abc-is-run/ what-guides-us/our-editorial-policies/ ABC Editorial Policies Management of The ABC Editorial Policies and associated editorial matters guidance outline the principles and set the In April 2016, the role that had previously standards that govern ABC content, and are overseen editorial matters was expanded to a day-to-day reference for content makers.
    [Show full text]
  • Biomarker Signature Found for TB Infection
    MEDIA RELEASE 8 May 2020 Biomarker signature found for TB infection A group of leading Australian researchers have uncovered a unique blood-based biomarker signature in individuals infected by tuberculosis (TB). The presence of the biomarker signature, found through a simple blood test, allows individuals with infectious TB–including those with non-symptomatic early-stage disease– to be easily identified and treated. The finding, reported in the Journal of Infection, could be key in supporting health efforts to control and eventually eliminate the TB epidemic which is responsible for approximately 1.5 million deaths each year globally. “A major issue in controlling the spread of tuberculosis is the difficulty of detecting the disease quickly and effectively, particularly in developing countries and in remote areas where technology and testing facilities may be limited,” says lead author of the study, Dr Jennifer Ho from the Centenary Institute and the Woolcock Institute of Medical Research “Sputum smear microscopy is the test used to diagnose TB in the majority of endemic settings but it is unable to pick-up TB in its early stages which prevents timely diagnosis and treatment.” “Also problematical are individuals with latent TB who possess no physical sickness or symptoms,” she says. “Unaware they are infected, these individuals can become TB spreaders if their disease progresses at some point to an active state.” Dr Ho notes that it is estimated that over 3.3 million cases of active TB are undetected annually, contributing to the uncontrolled spread of TB. “Our biomarker discovery could be used as the basis for a highly effective and simple diagnostic blood test to help detect these prevalent cases of TB in the community,” she says.
    [Show full text]
  • Snow Fellowships 2020 Application Round - Eligible Host Organisations
    Snow Fellowships 2020 Application Round - Eligible Host Organisations Entity name Asbestos Diseases Research Institute Australian Catholic University Limited Australian Centre for Heart Health Australian Institute of Aboriginal and Torres Strait Islander Studies Australian National University Baker Heart and Diabetes Institute Bionics Institute Black Dog Institute Bond University Limited Brien Holden Vision Institute Burnet Institute Centenary Institute of Cancer Medicine and Cell Biology Central Australian Aboriginal Congress Aboriginal Corporation Central Queensland University Centre for Eye Research Australia Limited Charles Darwin University Charles Sturt University Children's Cancer Institute Children's Medical Research Institute Chris O'Brien Lighthouse Curtin University Deakin University Doherty Institute Ear Science Institute Australia Incorporated Edith Cowan University Federation University Australia Flinders University Florey Institute of Neuroscience and Mental Health Garvan Institute of Medical Research George Institute for Global Health Griffith University Hanson Institute Harry Perkins Institute of Medical Research Heart Research Institute Hudson Institute of Medical Research Hunter Medical Research Institute Ingham Institute Institute for Breathing and Sleep James Cook University Kolling Institute of Medical Research La Trobe University Lions Eye Institute Macquarie University Mater Research Limited Melanoma Institute Australia Menzies School of Health Research Monash University Murdoch Children’s Research Institute Murdoch
    [Show full text]
  • 2012 Annual Report (3.9MB PDF File)
    Annual Report RESEARCH2012 HIGHLIGHT OF THE YEAR Our group has made significant advances in understanding disease progression related to iron metabolism, but also on a more translational level, advances in characterising the effects of drug therapies in cancer. We have provided new insight into disease causing iron acquisition through a particular iron transporter, and have characterised specific lead drug candidates targeting the LAT transporters in prostate cancer cells. OUR HISTORY The Centenary Institute opened in 1989, under the stewardship of its founding Director Professor Anthony Basten, to commemorate the centenaries of the University of Sydney Medical School and the Royal Prince Alfred Hospital. Formal working relationships with the University and Hospital have provided unique opportunities for students to become involved both in research and the translation of basic discoveries into clinical practice, an area in which the Institute has become a leader. The Centenary Institute is a world class medical research facility focusing on cancer, cardiovascular and infectious diseases. It is located between Royal Prince Alfred Hospital and the University of Sydney, and forms a critical point of contact and intellectual engagement between the Hospital and the University. 2012 Scientific Image Prize Winner – ‘The Spark of Life’. Dr David Hancock, T cell Biology. Understanding the complexity of the immune system using advanced bioinformatics. A network map displaying all interactions in an immune cell after activation. Centenary Institute
    [Show full text]
  • 2014 Annual Report
    2014 ANNUAL REPORT Understanding CONTENTS DISEASE THE YEAR IN REVIEW RESEARCH LABS & GROUPS Chairman & Executive Ageing Director Report Agnes Ginges Disease of the Aorta 1 4 Bioinformatics ABOUT CENTENARY Cardiovascular Signalling Board of Governors Cellular Mechanobiology Scientific Advisory Board DNA Repair 2 Scientific Support Host Responses to TB Centenary Foundation Human Viral & Cancer Immunology Fundraising Committee Liver Cell Biology YCF Melanoma Cell Biology Community Fundraising Molecular Hepatology Origins of Cancer RESEARCH PROGRAMS Gene & Stem Cell Therapy HIGHLIGHTS & AWARDS Immune Imaging Financial Highlights 3 Liver Immunology 5 2014 Award Recipients Liver Injury and Cancer CI Lawrence Creative Prize Molecular Cardiology Structural Biology SCIENTIFIC EXCELLENCE T Cell Biology 2014 Publications Tuberculosis 6 Invited Presentations Vascular Biology Collaborations Grant Recipients Organisational Chart Finding a CURE 5 granting bodies last year. wide, we are now known CEO of Cochlear, In addition Serena Stewart, for initiating the Centenary who will join our Board of 1 2014 the new head of our Institute Lawrence Creative Governors in early 2015. Marketing and Fundraising Prize (CILCP), which IN REVIEW team, has systematically recognises the most Many thanks to Professor EXECUTIVE DIRECTOR MATHEW VADAS AO FAHMS | CHAIRMAN THE HON MICHAEL EGAN AO put into place a strategy talented young scientists Barbara Fazekas for her and developed a team to in Australia and promotes assistance and guidance significantly improve our their careers. during her term as There has never atmosphere, we look protecting our children fundraising capabilities Assistant Director. We also been a more back on 2014 as a and next generations from and engagement with More locally, we are thank Professor Wolfgang exciting time in hugely successful year some of the most chronic our donors (individual enthusiastic members of Weninger for his ongoing biomedical science.
    [Show full text]
  • 2020 Annual Report PHOTOGRAPH CREDITS: Pp
    Response and Recovery 2020 Annual Report PHOTOGRAPH CREDITS: pp. 13/18/back cover, Brett Summerell; p. 19, CDC/Alissa Eckert, MSMI; Dan Higgins, MAMS. Contents Chairman’s 2019/2020 Bioplatforms report Highlights Australia 2 4 5 Bioplatforms Bioplatforms Feature network activities stories 6 7 8 Network National Collaboration LEADERSHIP access Initiatives and partnerships Bioplatforms Australia is committed to maintaining a high standard of governance and leadership. Strategic direction and operational oversight is provided by an independent Board of Directors and supported by an Executive Management Committee who advise on platform technologies and organisational initiatives. Board Members and Responsibilities Executive Management Committee 10 13 16 Bioplatforms Australia’s Directors offer a wealth of experience The Executive Management Committee manages and advises across scientific, business and government domains. on platform issues and operations. It is also responsible for Industry Capabilities BioCommons Each Director has responsibility for particular aspects of implementing strategic initiatives, including Commonwealth engagement network organisational strategy in addition to their fiduciary duties. funding agreements established with network partners. Dr Leslie Trudzik – Chairman Committee members are: Les is a founding Board Member of Bioplatforms Australia and Chair became Chairman in 2013. He is responsible for developing the Andrew Gilbert, Chief Executive, Bioplatforms Australia organisation’s performance and impact framework.
    [Show full text]
  • 2003 Annual Report
    Centenary Institute The Key of Life Annual Report 2002 – 2003 Centenary Institute of Cancer Medicine and Cell Biology Contents Centenary Institute 2 From the Director 3 Centenary Institute Annual Research 5 Review The Director’s Laboratory 6 Molecular Cardiology Laboratory 11 Immune Regulation Laboratory 14 Cancer Drug Resistence Laboratory 16 Liver Immunobiology Laboratory 19 Mycobacterial Research Laboratory 24 T Cell Biology Laboratory 27 Gene Therapy Laboratory 32 Research Funding 2002/ 03 35 Publications 2002 /03 37 Board of Governors 43 Institute Staff 45 - 1 - Centenary Institute The Centenary Institute of Cancer Medicine and Cell Biology is a centre of excellence in medical research. The Institute specialises in the diagnosis, prevention and treatment of diseases ranging from cancer, Type 1 Diabetes and allergy, to genetic heart disease and tuberculosis. Our strategy is to undertake ‘cutting edge’ research into the biology of normal and diseased cells, with the goal of improving our understanding of what causes disease and to translate these discoveries into clinical practice through development of new vaccines, better diagnostic tests and innovative forms of treatment. The Centenary Institute was conceived in 1982 to commemorate the Centenaries of the University of Sydney Medical School and the Royal Prince Alfred Hospital. Formal affiliations with both organisations promote the opportunities for students to become involved in research as well as the extrapolation of research theories to practice. The Institute is located in the grounds of Royal Prince Alfred Hospital adjacent to the Medical School and University Campus, in a purpose built facility capable of accommodating a research team of up to 150 career investigators, trainees and support staff.
    [Show full text]